Johnson & Johnson (JNJ) Buy, Sell or Hold

Home

Daily Stock Opinions and Ratings

Johnson & Johnson (JNJ)

Wealthica The ultimate 360° Tracker Your financial life in one place, automatically

232.16

-0.61 (0.26%)

as of Jun 8, 2026, 8:00:00 pm Market Open.

698 watching

Investor Insights

Jun 8, 2026, 12:00 am

This summary was created by AI, based on 12 opinions in the last 12 months.

Johnson & Johnson (JNJ) has been experiencing a transformative period, especially following the spinoff of its orthopedics division, allowing it to focus more on pharmaceuticals and medical devices. Experts have highlighted the company's strong drug pipeline and robust performance in its core pharmaceutical business, which has led to a significant increase in stock value this year. Despite some concerns regarding ongoing talcum powder litigation and its past underwhelming performance, many analysts believe the legal risks are diminishing. The stock is seen as a better long-term hold, with potential dividend growth, especially amidst a broader economic context affecting consumer products. Overall, JNJ is viewed as an attractive investment, particularly when bought on weakness, with the valuation appearing favorable due to its premium position in the healthcare sector.

Consensus

Buy

Valuation

Fair Value

Similar

TRADE

The only drug company they own and it is for the medical devices and for the consumer products rather than the pharmaceuticals.

TRADE

Has the best fundamentals of all the drug stocks. Drug sector has come under a number of significant pressures.

BUY

A great company. Feels the US$ will drop so there is a modest exchange risk.

BUY

May be considered boring, but the stability in terms of earnings is going to work well as a theme in the sector.

BUY

Widely diversified product line and not like normal pharmaceutical companies.

TOP PICK

A great business. Low valuation.

TOP PICK

Good ballast for portfolios. Cheap valuation.

TOP PICK

2% yield. Didn't do much over the last year but is starting to recover with different products. On a valuation basis compared to their peers, they are at a much deeper discount. A safe investment.

TOP PICK

Pays a little over 2% dividend. A multitude of products. Terrific track record of making money. A safe place to be in uncertain times.

TOP PICK

With the feds tightening and profit growths slowing, the market is going ahead for higher quality stocks. A well-run company and is not expensive.

BUY

Likes the longer-term outlook for pharmaceuticals. Historically, they have performed relatively well when interest rates are going up.

BUY

Health-care sector is the best sector to be in. Can't think of anything better than this stock. Wide range of products.

DON'T BUY

Big pharmas have a problem of being too big and gets more leverage through Boston Scientific.

TOP PICK

Very high-quality stock.

BUY

A great blue-chip company. A wonderful line of consumer products, some good pharmaceuticals and, making money on their coated stent. This stock will not have fast growth.

Showing 571 to 585 of 626 entries

Most Recent Experts

Jim Cramer - Mad Money

CNBC

Larry Berman CFA, CMT, CTA

ETF Capital Management Inc.

Mike Vinokur, CFA, CMT, and CFP

Propellus Wealth Partners/iA Private Wealth

Brian Madden

First Avenue Investment Counsel

The Panic-Proof Portfolio (Stockchase Research)

Stockchase Premium

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : [email protected].

Johnson & Johnson (JNJ)